BACKGROUND: The treatment of relapsed and refractory leukemia in children remains a challenge. The morbidity of further chemotherapy is considerable, as most patients have already been exposed to intensive multiagent chemotherapy. The FLAG (fludarabine, high-dose cytarabine, and G-CSF) regimen is as intensive but less cardiotoxic because of the avoidance of anthracyclines. PROCEDURE: Nineteen children were treated in two U.K. centers with the FLAG regimen for relapsed and refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). There were 13 males and 6 females, with an age range of 1.9 to 14.2 years. AML was the diagnosis in 12 children, ALL in 4, biphenotypic leukemia in 3. Eight patients had refractory disease, 11 were in relapse (5 in first relapse, 4 in second, and 2 in third). RESULTS: Complete remission was obtained in 13 patients, partial remission was obtained in 4, and 2 patients were considered nonresponders. There were seven patients alive at 12 months (mean) posttherapy; one of these is awaiting bone marrow transplantation (BMT). All patients experienced grade 4 hematological toxicity; no patient died of infection. Thirteen patients received BMT as consolidation (seven unrelated donor; six sibling allografts). Six of these have died, four due to pneumonitis. CONCLUSIONS: FLAG can be regarded as an effective protocol for inducing remission in a group of heavily pretreated children. Its toxicity is acceptable due to the avoidance of anthracyclines.
BACKGROUND: The treatment of relapsed and refractory leukemia in children remains a challenge. The morbidity of further chemotherapy is considerable, as most patients have already been exposed to intensive multiagent chemotherapy. The FLAG (fludarabine, high-dose cytarabine, and G-CSF) regimen is as intensive but less cardiotoxic because of the avoidance of anthracyclines. PROCEDURE: Nineteen children were treated in two U.K. centers with the FLAG regimen for relapsed and refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). There were 13 males and 6 females, with an age range of 1.9 to 14.2 years. AML was the diagnosis in 12 children, ALL in 4, biphenotypic leukemia in 3. Eight patients had refractory disease, 11 were in relapse (5 in first relapse, 4 in second, and 2 in third). RESULTS: Complete remission was obtained in 13 patients, partial remission was obtained in 4, and 2 patients were considered nonresponders. There were seven patients alive at 12 months (mean) posttherapy; one of these is awaiting bone marrow transplantation (BMT). All patients experienced grade 4 hematological toxicity; no patient died of infection. Thirteen patients received BMT as consolidation (seven unrelated donor; six sibling allografts). Six of these have died, four due to pneumonitis. CONCLUSIONS: FLAG can be regarded as an effective protocol for inducing remission in a group of heavily pretreated children. Its toxicity is acceptable due to the avoidance of anthracyclines.
Authors: Lisa A Hammond-Thelin; Melanie B Thomas; Michiko Iwasaki; James L Abbruzzese; Yvonne Lassere; Christina A Meyers; Paulo Hoff; Johann de Bono; Jody Norris; Hitoshi Matsushita; Akira Mita; Eric K Rowinsky Journal: Invest New Drugs Date: 2010-09-14 Impact factor: 3.850
Authors: Michael J Joyce; Brad H Pollock; Meenakshi Devidas; George R Buchanan; Bruce Camitta Journal: J Pediatr Hematol Oncol Date: 2013-01 Impact factor: 1.289
Authors: Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita Seibel; Margie Weiman; Kathryn Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo Journal: Blood Date: 2007-11-13 Impact factor: 22.113
Authors: Sima Jeha; Bassem Razzouk; Michael Rytting; Susan Rheingold; Edythe Albano; Richard Kadota; Lori Luchtman-Jones; Lisa Bomgaars; Paul Gaynon; Stewart Goldman; Kim Ritchey; Robert Arceci; Arnold Altman; Kimo Stine; Laurel Steinherz; Peter Steinherz Journal: J Clin Oncol Date: 2009-08-03 Impact factor: 44.544
Authors: Jeffrey J Bednarski; Clare Zimmerman; Melissa M Berrien-Elliott; Jennifer A Foltz; Michelle Becker-Hapak; Carly C Neal; Mark Foster; Timothy Schappe; Ethan McClain; Patrick P Pence; Sweta Desai; Samantha Kersting-Schadek; Pamela Wong; David A Russler-Germain; Bryan Fisk; Wen-Rong Lie; Jeremy Eisele; Stephanie Hyde; Sima T Bhatt; Obi L Griffith; Malachi Griffith; Allegra A Petti; Amanda F Cashen; Todd A Fehniger Journal: Blood Date: 2022-03-17 Impact factor: 25.476